Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Shares Issued (2016 - 2024)

Rocket Pharmaceuticals' Shares Issued history spans 8 years, with the latest figure at $321000.0 for Q4 2024.

  • For Q4 2024, Shares Issued changed N/A year-over-year to $321000.0; the TTM value through Sep 2025 reached $321000.0, down 88.89%, while the annual FY2024 figure was $3.2 million, 45771.43% up from the prior year.
  • Shares Issued for Q4 2024 was $321000.0 at Rocket Pharmaceuticals, up from $176000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $17.2 million in Q1 2023 and bottomed at -$15.9 million in Q2 2023.
  • The 5-year median for Shares Issued is $127500.0 (2022), against an average of $361000.0.
  • The largest YoY upside for Shares Issued was 16488.68% in 2021 against a maximum downside of 330133.33% in 2021.
  • A 5-year view of Shares Issued shows it stood at $2.6 million in 2020, then plummeted by 487.29% to -$9.9 million in 2021, then surged by 99.2% to -$79000.0 in 2022, then tumbled by 1531.65% to -$1.3 million in 2023, then skyrocketed by 124.9% to $321000.0 in 2024.
  • Per Business Quant, the three most recent readings for RCKT's Shares Issued are $321000.0 (Q4 2024), $176000.0 (Q3 2024), and $1.5 million (Q2 2024).